$MNOV
MEDICINOVA INC

2021 Q4 Form 10-K Financial Statement

#000156459022005388 Filed on February 16, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $0.00 $4.038M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $325.8K $5.715M $1.220M
YoY Change -73.29% -14.57% 205.0%
% of Gross Profit
Research & Development $1.777M $8.100M $1.800M
YoY Change -1.28% 14.08% -1.64%
% of Gross Profit
Depreciation & Amortization $6.370K $26.15K $0.00
YoY Change 22.52%
% of Gross Profit
Operating Expenses $2.103M $8.100M $3.010M
YoY Change -30.14% 14.08% 35.59%
Operating Profit -$10.22M
YoY Change
Interest Expense $36.47K $143.6K $40.00K
YoY Change -8.83% -60.1% -84.0%
% of Operating Profit
Other Income/Expense, Net -$14.21K -$59.50K -$10.00K
YoY Change 42.1% 48.75%
Pretax Income -$2.081M -$10.13M -$2.990M
YoY Change -30.42% -26.88% 51.78%
Income Tax $2.570K $2.568K $0.00
% Of Pretax Income
Net Earnings -$2.083M -$10.13M -$2.990M
YoY Change -30.33% -26.85% 51.01%
Net Earnings / Revenue -251.0%
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$42.47K -$208.5K -$66.50K
COMMON SHARES
Basic Shares Outstanding 48.60M
Diluted Shares Outstanding 48.60M

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $71.43M $71.43M $60.00M
YoY Change 19.05% 19.05% -5.96%
Cash & Equivalents $71.43M $71.43M $60.04M
Short-Term Investments
Other Short-Term Assets $578.0K $578.0K $700.0K
YoY Change -17.43% -17.43% 40.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $72.01M $72.01M $60.72M
YoY Change 18.6% 18.63% -5.58%
LONG-TERM ASSETS
Property, Plant & Equipment $57.57K $881.8K $55.70K
YoY Change 3.35% 781.78% 37.36%
Goodwill $9.600M $9.600M
YoY Change 0.0% 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $115.5K $115.5K $75.38K
YoY Change 53.22% -42.26% -83.61%
Total Long-Term Assets $15.40M $15.40M $14.70M
YoY Change 4.73% 4.74% -1.33%
TOTAL ASSETS
Total Short-Term Assets $72.01M $72.01M $60.72M
Total Long-Term Assets $15.40M $15.40M $14.70M
Total Assets $87.41M $87.41M $75.42M
YoY Change 15.89% 15.92% -4.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $402.7K $402.7K $616.6K
YoY Change -34.69% -32.88% 36.63%
Accrued Expenses $2.430M $2.430M $1.600M
YoY Change 51.89% 51.89% -11.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $2.833M $2.833M $2.194M
YoY Change 29.12% 28.77% -1.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $694.7K $694.7K $2.705K
YoY Change 25581.11% -59.14% -98.55%
Total Long-Term Liabilities $694.7K $694.7K $2.705K
YoY Change 25581.11% -59.14% -98.55%
TOTAL LIABILITIES
Total Short-Term Liabilities $2.833M $2.833M $2.194M
Total Long-Term Liabilities $694.7K $694.7K $2.705K
Total Liabilities $3.729M $3.729M $4.093M
YoY Change -8.88% -9.04% -5.06%
SHAREHOLDERS EQUITY
Retained Earnings -$393.1M -$382.9M
YoY Change 2.65% 3.75%
Common Stock $476.8M $454.3M
YoY Change 4.95% 2.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $83.68M $83.68M $71.33M
YoY Change
Total Liabilities & Shareholders Equity $87.41M $87.41M $75.42M
YoY Change 15.89% 15.92% -4.78%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$2.083M -$10.13M -$2.990M
YoY Change -30.33% -26.85% 51.01%
Depreciation, Depletion And Amortization $6.370K $26.15K $0.00
YoY Change 22.52%
Cash From Operating Activities -$3.639M -$9.382M -$1.950M
YoY Change 86.61% -13.34% -18.75%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $28.73K -$40.00K
YoY Change -100.0% -21.26% 300.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities $0.00 -$28.73K -$40.00K
YoY Change -100.0% -21.26% 300.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 38.70K 20.78M 360.0K
YoY Change -89.25% 192.41% -89.22%
NET CHANGE
Cash From Operating Activities -3.639M -9.382M -1.950M
Cash From Investing Activities 0.000 -28.73K -40.00K
Cash From Financing Activities 38.70K 20.78M 360.0K
Net Change In Cash -3.600M 11.39M -1.630M
YoY Change 120.88% -403.37% -275.27%
FREE CASH FLOW
Cash From Operating Activities -$3.639M -$9.382M -$1.950M
Capital Expenditures $0.00 $28.73K -$40.00K
Free Cash Flow -$3.639M -$9.410M -$1.910M
YoY Change 90.52% -13.37% -20.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 mnov Employee Stock Purchase Plan Offering Period
EmployeeStockPurchasePlanOfferingPeriod
P6M
CY2021 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M14D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P10M9D
CY2021Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OtherLiabilitiesNoncurrent
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
9937567
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Auditor Name
AuditorName
BDO USA, LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, California
CY2021 dei Auditor Firm
AuditorFirmId
243
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
71430954
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
60036763
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
577992
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
680171
CY2021Q4 us-gaap Assets Current
AssetsCurrent
72008946
CY2020Q4 us-gaap Assets Current
AssetsCurrent
60716934
CY2021Q4 us-gaap Goodwill
Goodwill
9600240
CY2020Q4 us-gaap Goodwill
Goodwill
9600240
CY2021Q4 mnov In Process Research And Development
InProcessResearchAndDevelopment
4800000
CY2020Q4 mnov In Process Research And Development
InProcessResearchAndDevelopment
4800000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57565
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55700
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
824215
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
170857
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
115492
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
75379
CY2021Q4 us-gaap Assets
Assets
87406458
CY2020Q4 us-gaap Assets
Assets
75419110
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
402740
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
616629
CY2021Q4 mnov Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2298203
CY2020Q4 mnov Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1391293
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
131965
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
186028
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2832908
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2193950
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1694163
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
201792
CY2020Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
201792
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
694674
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2705
CY2021Q4 us-gaap Liabilities
Liabilities
3729374
CY2020Q4 us-gaap Liabilities
Liabilities
4092610
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
49043246
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
49043246
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45024560
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45024560
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
49043
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
45025
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
476788012
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
454296536
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-98877
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-88219
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-393061094
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-382926842
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
83677084
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
71326500
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87406458
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75419110
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
4037500
CY2021 mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
8538027
CY2020 mnov Research Development And Patents Expense
ResearchDevelopmentAndPatentsExpense
7484835
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6693488
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10131684
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13855545
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-13853897
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3175553
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
11708
CY2020 mnov Stock Issued During Period Value Under At The Market Equity Distribution And Sales Agreements
StockIssuedDuringPeriodValueUnderAtTheMarketEquityDistributionAndSalesAgreements
6188079
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
905972
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-13853897
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
4462
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
71326500
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1717513
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6110
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19881632
CY2021 us-gaap Profit Loss
ProfitLoss
-10134252
CY2020 us-gaap Profit Loss
ProfitLoss
-13853897
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1717513
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
3175553
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26149
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21342
CY2021 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-286
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
216640
CY2020 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
210213
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-50319
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
155259
CY2021 mnov Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities
-1026525
CY2020 mnov Increase Decrease In Accounts Payable Accrued Liabilities And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedLiabilitiesAndOtherLiabilities
-4772
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-231735
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-219542
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9381605
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10826362
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28732
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36492
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28732
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-36492
CY2021 mnov Proceeds From Issuance Of Common Stock Exercise Of Common Stock Options
ProceedsFromIssuanceOfCommonStockExerciseOfCommonStockOptions
20890239
CY2020 mnov Proceeds From Issuance Of Common Stock Exercise Of Common Stock Options
ProceedsFromIssuanceOfCommonStockExerciseOfCommonStockOptions
7297891
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
118368
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
203840
CY2021 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
6110
CY2020 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
11708
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20777981
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7105759
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26547
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
1201
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
11394191
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3755894
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60036763
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63792657
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71430954
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
60036763
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
1485
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
870373
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
170857
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:2.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and the accompanying notes. Actual results could differ from those estimates.</p>
CY2020Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
17191
CY2021Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
124731
CY2020Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
244021
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Concentrations and Credit Risk</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:2.78%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company maintains cash balances at various financial institutions and such balances commonly exceed the $250,000 amount insured by the Federal Deposit Insurance Corporation. The Company also maintains money market funds at various financial institutions which are not federally insured although are invested primarily in U.S. government securities. The Company has not experienced any losses in such accounts and management believes that the Company does not have significant credit risk with respect to such cash and cash equivalents.</p>
CY2021Q4 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000
CY2021Q4 mnov Clinical Trial Accruals
ClinicalTrialAccruals
1100000
CY2021Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
400000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8100000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7100000
CY2021 mnov Patents Expense
PatentsExpense
400000
CY2020 mnov Patents Expense
PatentsExpense
400000
CY2021Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
342628
CY2020Q4 us-gaap Capitalized Computer Software Gross
CapitalizedComputerSoftwareGross
318105
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
482768
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
579317
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
425203
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
523617
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57565
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
55700
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
26149
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
21342
CY2020Q4 mnov Clinical Trial Accruals
ClinicalTrialAccruals
400000
CY2020Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
500000
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7974250
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7401387
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
248648
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
228779
CY2021Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
15409
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
636481
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
823254
CY2021Q4 mnov Clinical Trial Accruals Current
ClinicalTrialAccrualsCurrent
1076411
CY2020Q4 mnov Clinical Trial Accruals Current
ClinicalTrialAccrualsCurrent
401789
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
38041
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
65207
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
547270
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
101043
CY2021Q4 mnov Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
2298203
CY2020Q4 mnov Accrued Liabilities And Other Liabilities Current
AccruedLiabilitiesAndOtherLiabilitiesCurrent
1391293
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
242676
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
240467
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
870373
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
131965
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
186028
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
694674
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2705
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
826639
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
188733
CY2021Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.098
CY2020Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.088
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
210816
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
221104
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
189170
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
197586
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
206483
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
17269
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1042428
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
215789
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
826639
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.61
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1382000
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.67
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
287863
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.15
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
8.73
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.70
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M1D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
32840
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
5700000
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
32840
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.82
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.47
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
6687917
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
5.81
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1280500
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.74
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
5700000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
4200000
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
3700000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.51
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1133167
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
3.70
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
176000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
3.81
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1286333
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
3.54
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
700000
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
700000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M21D
CY2021 mnov Stock Issuance Limit Under Employee Stock Purchase Plan Description
StockIssuanceLimitUnderEmployeeStockPurchasePlanDescription
shares reserved automatically increase each year by a number equal to the lesser of: (i) 15,000 shares; (ii) 1% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year; or (iii) such lesser amount as determined by the Board
CY2021 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
1424
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.70
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1717513
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3175553
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-10145822
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-13865784
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
14138
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
10239
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10131684
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13855545
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
2568
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-1648
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
2568
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-1648
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2568
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1648
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
68485037000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
67403329000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
30784000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense
DeferredTaxAssetsTaxDeferredExpense
98411000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
9262071000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8980935000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1601862000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2902963000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
423279000
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
770100000
CY2021Q4 mnov Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
196059000
CY2020Q4 mnov Deferred Tax Assets Right Of Use Asset
DeferredTaxAssetsRightOfUseAsset
39615000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
79999092000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
80195353000
CY2021Q4 mnov Deferred Tax Liabilities Right Of Use Liability
DeferredTaxLiabilitiesRightOfUseLiability
196059000
CY2020Q4 mnov Deferred Tax Liabilities Right Of Use Liability
DeferredTaxLiabilitiesRightOfUseLiability
35726000
CY2021Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1343213000
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Research And Development Costs
DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts
1343213000
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1539272000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1378939000
CY2021Q4 mnov Deferred Tax Assets Liabilities Before Valuation Allowance
DeferredTaxAssetsLiabilitiesBeforeValuationAllowance
78459820000
CY2020Q4 mnov Deferred Tax Assets Liabilities Before Valuation Allowance
DeferredTaxAssetsLiabilitiesBeforeValuationAllowance
78816414000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
78661612000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
79018206000
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
201792000
CY2020Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
201792000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
400000
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.027
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.052
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.028
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.021
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.035
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.214
CY2021 mnov Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
-0.002
CY2021 mnov Effective Income Tax Rate Reconciliation Expiration Of Attribute
EffectiveIncomeTaxRateReconciliationExpirationOfAttribute
-0.104
CY2020 mnov Effective Income Tax Rate Reconciliation Expiration Of Attribute
EffectiveIncomeTaxRateReconciliationExpirationOfAttribute
-0.018
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.124
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
-0.052
CY2021 mnov Effective Income Tax Rate Reconciliation Uncertain Tax Position
EffectiveIncomeTaxRateReconciliationUncertainTaxPosition
-0.070
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.001
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
893371
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
893371
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
72330
CY2020 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
81647

Files In Submission

Name View Source Status
0001564590-22-005388-index-headers.html Edgar Link pending
0001564590-22-005388-index.html Edgar Link pending
0001564590-22-005388.txt Edgar Link pending
0001564590-22-005388-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mnov-10k_20211231.htm Edgar Link pending
mnov-10k_20211231_htm.xml Edgar Link completed
mnov-20211231.xsd Edgar Link pending
mnov-20211231_cal.xml Edgar Link unprocessable
mnov-20211231_def.xml Edgar Link unprocessable
mnov-20211231_lab.xml Edgar Link unprocessable
mnov-20211231_pre.xml Edgar Link unprocessable
mnov-ex231_11.htm Edgar Link pending
mnov-ex311_9.htm Edgar Link pending
mnov-ex312_7.htm Edgar Link pending
mnov-ex321_10.htm Edgar Link pending
mnov-ex322_8.htm Edgar Link pending
mnov-ex4_6.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending